Neurology Clinical Trials Market By Disease Type (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Epilepsy, Other Neurological Disorders), By Phase of Development (Preclinical Trials, Phase I Trials, Phase II Trials, Phase III Trials, Phase IV Trials), By Type of Trial (Interventional Trials, Observational Trials), By End-User (Pharmaceutical Companies, Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Neurology Clinical Trials Market was valued at USD 5.7 Billion in 2024-e and will surpass USD 7.8 Billion by 2030; growing at a CAGR of 5.4% during 2025-2030.

The neurology clinical trials market is driven by the increasing prevalence of neurological disorders globally, including Alzheimer’s, Parkinson’s, and epilepsy. With a growing understanding of these diseases and advancements in treatment options, the demand for clinical trials has surged. Pharmaceutical companies, biotechnology firms, and research institutions are intensifying their focus on developing effective therapies for these conditions, leading to a thriving clinical trials landscape. As new treatments and technologies emerge, clinical trials have become essential in ensuring their safety and efficacy.

Alzheimer’s Disease Segment Is Largest Owing to High Prevalence

Alzheimer’s disease remains the largest segment within neurology clinical trials, driven by the aging global population and increasing incidence rates. As one of the most common neurodegenerative diseases, Alzheimer’s affects millions of individuals worldwide, making it a prime focus for pharmaceutical companies and research institutions. The demand for clinical trials for Alzheimer’s treatments is soaring as new drug candidates aimed at slowing or halting the disease’s progression enter the market. The need for therapies that target the underlying mechanisms of Alzheimer’s, such as amyloid plaques and tau tangles, further boosts the volume of trials.

The Alzheimer’s disease segment is expected to continue growing due to ongoing research in biomarkers, disease-modifying therapies, and innovative treatment approaches. Pharmaceutical companies are investing heavily in clinical trials, aiming to find breakthrough treatments. The launch of several promising drugs and therapies in late-stage clinical trials is expected to increase the number of studies and result in market expansion in the coming years.

Phase III Trials Are Fastest Growing Due to Clinical Validation Needs

Phase III trials are experiencing the fastest growth in the neurology clinical trials market, primarily due to the increasing number of drugs and therapies advancing to this stage of development. Phase III trials are crucial for validating the efficacy and safety of a drug in a large patient population, and this stage is often the deciding factor for regulatory approval. As neurological disorders continue to demand new therapeutic options, the need for Phase III trials has escalated, particularly in diseases like Alzheimer’s and Parkinson’s, where several promising drugs are progressing through the pipeline.

The increasing investment in Phase III trials is also driven by the involvement of large pharmaceutical companies aiming to gain approval from regulatory bodies such as the FDA and EMA. The results from Phase III trials often determine the trajectory of a drug's market availability and adoption, making them a key focus in the clinical trials landscape.

Interventional Trials Are Largest Segment Due to High Treatment Development Focus

Interventional trials represent the largest segment in the neurology clinical trials market, as these trials are designed to assess new treatments, drugs, or procedures aimed at improving patient outcomes. These trials often involve the administration of experimental drugs, gene therapies, or medical devices and are essential for obtaining regulatory approval. Given the continuous development of novel neurological treatments, particularly for conditions like Parkinson’s and Alzheimer’s, interventional trials are a critical component of the research and development process.

With increasing research into disease-modifying treatments for conditions like multiple sclerosis and Alzheimer’s, the volume of interventional trials continues to rise. These trials are vital to demonstrating the effectiveness of new drugs and therapies, driving their success in the competitive market. As pharmaceutical companies prioritize the development of these treatments, the interventional trials segment will likely maintain its dominance.

Pharmaceutical Companies Are Leading End-User Segment Due to Robust R&D Investments

Pharmaceutical companies are the largest end-user segment in the neurology clinical trials market. These companies have extensive research and development (R&D) pipelines focused on neurological disorders, investing significantly in clinical trials to bring innovative treatments to market. The large-scale investment in R&D by pharmaceutical companies is propelled by the high unmet need for effective therapies in conditions like Alzheimer’s and Parkinson’s, which remain largely without effective treatment options.

These companies drive the neurology clinical trials market by funding trials, managing clinical study operations, and collaborating with contract research organizations (CROs) to streamline the process. Pharmaceutical companies also play a significant role in clinical trial design, patient recruitment, and ensuring regulatory compliance, which further boosts their influence in the market. Their ongoing commitment to neurological research underscores their pivotal role in the growth of the market.

North America Dominates the Market Owing to High Research Activity

North America is the largest region in the neurology clinical trials market, driven by substantial investments in healthcare infrastructure, research funding, and regulatory support for clinical trials. The United States, in particular, hosts a large number of clinical trial studies, especially in neurological diseases like Alzheimer’s and Parkinson’s. With well-established clinical trial networks, skilled healthcare professionals, and strong support from regulatory bodies such as the FDA, North America remains at the forefront of neurology clinical trial activity.

The region’s dominance is also supported by the presence of major pharmaceutical companies and CROs that frequently collaborate on large-scale clinical trials. Moreover, government funding and initiatives aimed at accelerating drug development in neurology contribute to the region's market share. North America's leadership in research, innovation, and regulatory framework makes it the hub for neurology clinical trials.

Competitive Landscape and Leading Companies

The neurology clinical trials market is highly competitive, with several large pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) dominating the space. Companies such as Pfizer Inc., Eli Lilly, Biogen Inc., and Novartis are at the forefront of neurological research and clinical trials, driving market innovations and investments. These companies have established strong research pipelines and partnerships, focusing on developing novel treatments for neurological diseases with high unmet needs.

Contract research organizations (CROs) such as IQVIA and PAREXEL International also play a vital role in conducting and managing clinical trials. These organizations support pharmaceutical companies by providing expertise in trial design, patient recruitment, data collection, and regulatory compliance. The competitive landscape is characterized by ongoing collaborations between pharmaceutical firms and CROs, as well as increasing mergers and acquisitions in the industry to strengthen R&D capabilities. With numerous therapies in development, the market is poised for growth, and competition will continue to intensify as companies seek to bring innovative neurological treatments to market.

List of Leading Companies:

• Novartis International AG
• Pfizer Inc.
• Eli Lilly and Co.
• Bristol-Myers Squibb
• Roche Holding AG
• Merck & Co., Inc.
• Sanofi S.A.
• AstraZeneca
• Johnson & Johnson Services, Inc.
• GlaxoSmithKline (GSK)
• Biogen Inc.
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Amgen Inc.
• UCB S.A.

Recent Developments:

• Pfizer announced the launch of a new Phase III clinical trial for an Alzheimer’s disease treatment, focusing on the drug’s ability to slow cognitive decline in patients.
• Biogen and Eisai announced a partnership to conduct joint clinical trials for a new Alzheimer’s disease drug, aiming for better efficacy and safety profiles in the early stages of the disease.
• Merck announced the successful progression of a Phase II clinical trial for a new Parkinson’s disease drug, demonstrating promising results in motor symptom improvement.
• Sanofi received FDA approval for a new epilepsy drug, following the completion of a large-scale Phase III clinical trial that demonstrated improved seizure control in patients.
• AstraZeneca successfully completed a Phase III trial for a new multiple sclerosis treatment, showing significant improvements in relapse rates and disease progression.

Report Scope: